Aminopyrimidines as ALK inhibitors
AssigneeThe Regents of the University of Michigan
InventorsShaomeng Wang, Jianyong Chen
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.
Claims18
A method of treating a patient comprising administering to the patient a therapeutically effective amount of a compound having Formula I, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the patient has a cancer in which anaplastic lymphoma kinase (ALK) has a role and the compound of Formula I has a structure:
- or a pharmaceutically acceptable salt or solvate thereof, wherein:
- Rla and R1b are independently selected from the group consisting of hydrogen, C1-6 alkyl, and C3-8 cycloalkyl;
- R2a and R2b are independently selected from the group consisting of hydrogen, C1-6 alkyl, and C3-8 cycloalkyl;
- R3 is selected from the group consisting of hydrogen, C1-6 alkyl, C3-6 cycloalkyl, and C4-8 heterocyclo,
- R4 is selected from the group consisting of C1-4 alkyl, and C3-6 cycloalkyl;
- R5 is halo;
- R6 is selected from the group consisting of C1-4 alkyl, and C3-6 cycloalkyl;
- and
- R7 is selected from the group consisting of hydrogen, C1-4 alkyl, and C3-6 cycloalkyl, with proviso that when R1a, R1b, R2a, and R2b are each hydrogen, then R3 is selected from the group consisting of C3-6 cycloalkyl and C4-8 heterocyclo.
A kit comprising the compound having Formula I or a pharmaceutically acceptable salt thereof, and instructions for administering the compound, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, to a patient having cancer in which anaplastic lymphoma kinase (ALK) has a role, wherein the compound of Formula I has a structure:
- or a pharmaceutically acceptable salt or solvate thereof, wherein:
- R1a and R1b are independently selected from the group consisting of hydrogen, C1-6 alkyl, and C3-8 cycloalkyl;
- R2a and R2b are independently selected from the group consisting of hydrogen, C1-6 alkyl, and C3-8 cycloalkyl;
- R3 is selected from the group consisting of hydrogen, C1-6 alkyl, C3-6 cycloalkyl, and C4-8 heterocyclo,
- R4 is selected from the group consisting of C1-4 alkyl, and C3-6 cycloalkyl;
- R5 is halo;
- R6 is selected from the group consisting of C1-4 alkyl, and C3-6 cycloalkyl;
- and
- R7 is selected from the group consisting of hydrogen, C1-4 alkyl, and C3-6 cycloalkyl,
- with proviso that when Rla, R1b, R2a, and R2b are each hydrogen, then R3 is selected from the group consisting of C3-6 cycloalkyl and C4-8 heterocyclo.
Dependencies are inferred from the claim text.